Background and objective: High-altitude pulmonary oedema (HAPE) is a non-cardiogenic hydrostatic oedema involving a genetic component. Considering the low incidence of HAPE, sample sizes in current reports are relatively limited. We aimed to assess the association between the angiotensin-converting enzyme (ACE) I/D polymorphism and HAPE via a meta-analysis of published and unpublished data. Materials and methods: We searched PubMed, CBM, CNKI, and Cochrane Library Database before 20 November 2010. A random-effects model was applied (STATA) and study quality was assessed in duplicate. Results: A total of five studies including 305 cases and 662 controls were meta-analysed. The summary odds ratio (OR) indicated that no significant differences in risk of developing HAPE were found between carriers of ACE D and I alleles (OR = 1.20; 95% confidence interval (CI), 0.98-1.48; p = 0.084). Lack of association persisted for genotypes under the recessive mode. However, genotype association under the dominant mode showed D allele carriers significantly conferred a 1.55-fold increased HAPE risk compared with II genotype carriers (95% CI, 1.15-2.08; p = 0.004). Funnel plot and Egger's test suggested no evidence of publication bias. Conclusions: Our results supported the notion that ACE D allele carriers were at significant increased risk of developing HAPE.
Introduction
High-altitude pulmonary oedema (HAPE) is a life-threatening form of non-cardiogenic hydrostatic oedema that occurs in otherwise healthy people at altitudes exceeding 2500 m above sea level. 1, 2 Some individuals are more likely to develop HAPE at high altitudes, and its development is likely under genetic control. A great number of candidates have been listed as HAPE susceptibility genes, 3 such as the genes of angiotensin-converting enzyme (ACE) and angiotensin II type 1 receptor, which are the major bioactive components in the renin-angiotensin system [4] [5] [6] [7] , endothelin-1, 7 heat shock protein 70 family, 8 endothelial nitric oxide synthase, 9, 10 tyrosine hydroxylase, 11 and vascular endothelial growth factor. 12 However, determining how many genes and which genetic determinants are actually involved in the development of HAPE remains a challenge.
In the search for the inheritable determinants of HAPE, the gene encoding ACE (chromosome 17q23) ranks high. ACE-catalysed generation of angiotensinogen II can modulate the pulmonary vasoconstrictive response to hypoxia via the interaction with its receptor. 13 As Cargill and Lipworth showed that ACE inhibition might be a useful adjunctive treatment in hypoxaemic pulmonary hypertension, 14 it is reasonably expected that plasma ACE concentrations can serve as a strong predictor of HAPE risk. Observations have proposed that there is wide inter-individual variability of plasma ACE levels, and approximately half of this variability might be explained by the insertion/deletion (I/D) polymorphism of the human ACE gene. 15 Previous studies have indicated that the I allele is associated with decreased plasma ACE levels 16 and enhanced performance and adaptation at high altitudes. 17, 18 Due to the rareness of HAPE, only limited data are currently available. It is generally believed that a large sample size can yield a convincing result. To systematically address this issue, we performed a meta-analysis using both published studies and our own unpublished data in order to assess the association of ACE I/D polymorphism with HAPE.
Methods

Literature search
PubMed, the Chinese Biological Medicine Database (CBM), the Chinese Journals Full-text Database (CNKI), and the Cochrane Library Database were employed for searching publications, with the last update on 20 November 2010. Publications were identified by Boolean combinations of the key terms (high altitude pulmonary edema OR HAPE) AND (angiotensin converting enzyme OR ACE) AND (gene OR variant OR polymorphism OR allele). Reference lists of the retrieved articles and systematic reviews were also checked for citations of studies that were not identified initially. Search results were limited to articles published in English and studies on humans.
Inclusion/exclusion criteria
Case-control studies were included in this meta-analysis regardless of sample size if they were dedicated to evaluate the association of ACE I/D polymorphism with HAPE among unrelated subjects, if genotyping was performed by validated methods, and if they provided sufficient information on the genotype or allele frequencies for estimating odds ratio (OR) and its corresponding 95% confidence interval (CI). All ORs were calculated against healthy controls. HAPE was diagnosed according to the standard criteria.
When genotype frequency was not reported, authors were contacted to obtain the relevant information. For duplicate publications, the study with the smaller dataset was excluded.
Data sources
The initial search strategy retrieved seven potentially relevant articles. Of them, six studies met the selection criteria [4] [5] [6] [7] 19, 20 ; two were then excluded because one focused on polymorphisms other than ACE I/D, 6 and the other had an overlapping dataset with duplicate publications. 4 Meanwhile, a set of large unpublished data sharing the same sampling source as the study by Luobu et al. 4 was included in this meta-analysis.
The unpublished study had a total of 631 subjects including 148 patients with HAPE and 483 age-, gender-, nationality-and working-matched healthy controls. All subjects were unrelated males who had been born and had lived at lower altitudes prior to being recruited during the period of July 2001 to June 2006, as previously described. 4, 6, 8 All individuals who had the onset of symptoms consistent with HAPE within 2-6 days at altitudes between 4000-5072 m were evaluated and had their diagnoses confirmed using standard criteria at hospitals in the vicinity of the construction sites where they worked. The controls were randomly selected from a pool of individuals working at the railway construction sites who remained healthy for at least 3 months after selection.
The genotyping of ACE I/D polymorphism was determined by a PCR and agarose gel electrophoresis method, with researchers blinded to the subjects' clinical status. 21 To ensure accuracy, the results of this method were confirmed by randomly sequencing 5% of the total samples.
Data extraction
Two authors (YQ and JS) independently extracted the following information from each study: first author's last name, year of publication, ethnicity of the population studied, number of subjects in each category, baseline information of the study population such as age, gender when available, and the counts of persons with different genotypes/alleles in cases and controls. Any discordance was settled by discussion and a consensus was finally reached. For the sake of consistency, continuous variables expressed as mean ± standard error were converted to mean ± standard deviation (SD).
Statistical analysis
In this meta-analysis, we assessed association of the ACE D allele and HAPE compared with the I allele (allelic model), as well as using the dominant genetic model (DD+ID versus II) and the recessive genetic model (DD versus ID+II). Unadjusted OR corresponding to a 95% CI was used to compare contrasts of alleles and genotypes between patients and controls.
Deviation from Hardy-Weinberg equilibrium was assessed using Pearson χ 2 test. The random-effects model using the DerSimonian and Laird method was employed to bring the individual effect-size estimates together irrespective of between-study heterogeneity. Heterogeneity was evaluated by the I 2 statistic, which was documented for the percentage of the observed between-study variability due to heterogeneity rather than chance with its values ranging 0-100% (I 2 = 0-25%, no heterogeneity; I 2 = 25-50%, moderate heterogeneity; I 2 = 50-75%, large heterogeneity; I 2 = 75-100%, extreme heterogeneity). 22, 23 Cumulative meta-analysis was performed according to the ascending date of publication in order to identify the influence of the first published study on the subsequent publications, and the evolution of the combined estimates over time.
Furthermore, in order to identify potentially influential studies, sensitivity analysis was undertaken by removing an individual study each time to check whether any of these estimates might bias the overall estimate. Likewise, subgroup analysis was conducted after stratifying studies performed on various ethnic/geographic populations.
Finally, evidence for publication bias was assessed using Egger's test and visual funnel plot inspection. The Egger's test detects funnel plot asymmetry by determining whether the intercept deviates significantly from zero in a regression of the standardised effect estimates against their precision.
Probability less than 0.05 was judged significant with the exception of the I 2 statistic and publication tests, where a significance level of less than 0.1 was chosen. 22, 23 All of the calculations were performed using STATA version 10.0 for Windows.
Results
Description of studies identified in meta-analysis
Along with our unpublished data, a total of five studies with 305 HAPE patients and 662 controls were finally meta-analysed. All studies contained genotype data except for one that had only allele counts. 20 The baseline characteristics for these qualified studies are presented in table 1. Four studies were conducted in Asians (Japanese, Indians and Chinese) and one in Caucasians. 19 The sample sizes ranged from 39-631. The frequencies of ACE D allele ranged from 0.35-0.46 for HAPE patients, and 0.30-0.44 for controls. Figure 1 shows the pooled analysis of ACE I/D allele association with HAPE. The summary OR under a randomeffects model indicated that no significant differences in risk of developing HAPE were found between carriers of ACE D and I allele (OR = 1.20; 95% CI, 0.98-1.48; p = 0.084). Considering that four out of five studies were performed in Asians and one in Caucasians, 19 we stratified our analysis by race and still failed to demonstrate a statistical significance in Asians (OR = 1.21; 95% CI, 0.98-1.51; p = 0.081). In addition, cumulative and sensitivity analyses remained insignificant with tiny fluctuations around the summary OR (data not shown).
Meta-analysis results
Since the study by Kumar et al. lacked the necessary information on ACE I/D genotypes, 20 we only performed genotype association for the remaining four studies. Similarly, lack of association persisted for genotypes under the recessive mode (DD versus ID+II) of inheritance (OR = 0.99; 95% CI, 0.53-1.85; p = 0.976) (figure 2). In contrast, genotype association under the dominant mode (DD+ID versus II) showed statistical significance, with D allele carriers conferring a 1.55-fold increased risk for HAPE compared with those with II genotype when hinged on the summary OR from the random-effects model (95% CI, 1.15-2.08; p = 0.004) ( figure 3 ).
Publication bias
Funnel plot (data not shown) and Egger's test were performed to assess evidence of publication bias. The resulting symmetrical funnel shape was consistent with an absence of publication bias in the Begg's funnel plot for contrasts of D allele versus I allele (p Egger's test = 0.558), dominant model (p Egger's test = 0.570) and recessive model (p Egger's test = 0.570).
Discussion
To the authors' knowledge, this is the first meta-analysis associating ACE I/D polymorphism with HAPE risk. Along with our previously unpublished data, a total of five studies involving 305 cases and 662 controls were finally meta-analysed. This meta-analysis demonstrated overall a statistically significant association with ACE D allele carriers conferring a 1.55-fold increased risk for HAPE compared with those with the II genotype under the dominant mode.
Although there is substantial evidence suggesting the molecular involvement of ACE in HAPE, few studies in human populations have found significant associations with the I/D polymorphism as a predisposing factor. 5, 19, 20 Considering the wide CIs generated by these associations, it is possible that the study power was insufficient to detect or replicate a real result. It is an inevitable problem for HAPE genetic identification because the incidence is relatively low, with estimates ranging from 0.1-4.0%. 1 However, this problem can be avoided to some extent when the meta-analysis is employed. 24 After taking all available studies together, we failed to detect significant allele contrast of ACE D allele versus I allele, whereas under the assumption of dominant mode of inheritance, we found that the D allele carriers (DD and ID) were 1.55 times more likely to develop HAPE compared with the II genotype carriers. After taking a fresh look at the individual associations of DD and ID genotypes with HAPE, we only observed a risk tendency, albeit insignificant, for the latter contrast (data not shown), which may somewhat reflect a phenomenon of heterozygote advantage during human evolution. In addition, from the aspect of the D allele distributions between Caucasians (0.44 in controls) and Asians (0.30-0.37 in controls), we expect that, if involved, there might be genetic heterogeneity in association of ACE I/D polymorphism with HAPE. Considering the fact that ACE I/D polymorphism accounts for about half of the total variance of plasma ACE, 15 and that it is likely that ACE, a major gene for the phenotypic variance, might interact with other genetic or non-genetic factors, this may hinder the detection of a modest contribution of an individual locus to HAPE. Indeed, we previously compared the genetic profiles of 140 HAPE patients and 144 controls and found that the homozygous genotype combination of ACE -240AA and 2350GG, CYP11B2 -344TT conferred high genetic susceptibility to HAPE. 6 Thus, considering the complex nature of HAPE, interactions between genes or polymorphisms are the norm rather than the exception. 25, 26 We must consider the results of this meta-analysis as preliminary until more studies considering genetic interaction confirm or refute these findings.
The present meta-analysis should be interpreted within the context of its limitations. First, because of the casecontrol design of all the included studies, it inevitably suffers from the weaknesses of this type of study, i.e. the inability to prove the existence of a causal relationship. 27 Second, due to the relative small number of eligible studies, we were unable to perform subgroup analyses by other confounders such as gender. Third, because most of these studies were performed in middle-aged males (mean age: 27.3-38.6 years), generalisation to females, and males of other age profiles, should be viewed with caution. Fourth, considering the intronic nature of ACE I/D polymorphism, it remains possible that this polymorphism is in linkage disequilibrium with another functional variant within or around the ACE gene that is actually responsible for plasma ACE variation. Last but not least, we only meta-analysed the association of ACE I/D polymorphism with HAPE, and did not evaluate other polymorphisms in this gene and other targeted genes that might be associated with HAPE. It is possible that the potential role of I/D polymorphism is diluted or masked by other gene-gene or gene-environment interactions.
Taken together, our results supported the notion that carriers of ACE D allele were at significant increased risk of developing HAPE under the dominant mode of inheritance. Further studies with larger study sample sizes or comprehensive genetic interaction data are warranted.
